NEW CHIEF OPERATIONS OFFICER (COO) TO I-TECH

Mintage Scientifics holding I-Tech strengthens its commercial and industrial capabilities by appointing Oliver Weigenand as Chief Operating Officer (COO). Oliver has formerly been holding various international executive positions within LANXESS Corporation.

In the newly installed position Oliver will hold responsibility for sales and delivery and will in this position also lead the development of I-Techs industrial capabilities. Through this important reinforcement I-Tech is ready to accelerate global growth of its all new marine active agent (biocide), Selektope®.

I am very pleased that Oliver has selected I-Tech and assumed the position as COO. With Olivers passion for driving growth, his international experience from high demanding positions and deep insights in the chemical and biocidal industry, we have the best possible line up to make a difference to the market, says Philip Chaabane, CEO at I-Tech AB.

Oliver has an impressive track record from his 8 years at LANXESS Corporation and has successfully held positions as Global Product Manager (including marine biocides) and has also served as a CEO of an SME within the LANXESS Corp. Oliver recently served as Vice President North and Central America at LANXESS and moves back to Europe. Oliver assumes his role as COO at I-Tech in Gothenburg on June 15th.

I am absolutely convinced, that Selektope technology is a unique opportunity to establish a new generation marine antifouling product , says Oliver Weigenand. I am thrilled to boost global market approach and to help strengthen I-Techs industrial footprint. There are a lot of great potentials in front of the I-Tech team, together we will continue to built a strong platform, to ensure sustainable long term growth of Selektope,

For more information please contact I-Tech CEO, Philip Chaabane, philip.chaabane@i-tech.se

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Media

Media

Documents & Links